(±) -Lisofylline
(±) -Lisofylline ((±) -Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research[1].
Product Specifications
CAS Number
6493-06-7
Product Name Alternative
(±) -Lisophylline
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Interleukin Related
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/racemic-lisofylline.html
Concentration
10mM
Purity
99.93
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1CCCCC(O)C)N(C)C2=C(N(C)C=N2)C1=O
Molecular Formula
C13H20N4O3
Molecular Weight
280.33
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501
References & Citations
[1]Yang Z, et al. Lisofylline: a potential lead for the treatment of diabetes. Biochem Pharmacol. 2005 Jan 1;69 (1) :1-5.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
![Cd3e Rat Monoclonal Antibody [Clone ID: KT3]](https://cdn.genprice.uk/genprice/uk/genprice3.webp)
Lentiviral human RPS14 shRNA (UAS) - Lentiviral human RPS14 shRNA (UAS) (25)
